Geulah Livshits from Chardan Capital sets a price target of $76 for CRSP, indicating a potential increase of 43.21%. CRISPR Therapeutics' gene-editing therapy, Casgevy, for sickle cell disease receives FDA approval, showcasing the company's innovative potential. Despite a fourth-quarter loss, CRSP's stock rose by 8.46% due to its collaboration with Vertex Pharmaceuticals and the growing adoption of Casgevy therapy.
CRISPR Therapeutics AG (NASDAQ: CRSP) is a leading biotech company specializing in gene editing. The company has gained attention for its innovative CRISPR-based technology, which allows for precise gene editing to treat diseases. CRISPR Therapeutics has already commercialized its technology, offering a revenue stream and potential for future growth. Its main competitor in the gene-editing space is Editas Medicine.
On February 14, 2026, Geulah Livshits from Chardan Capital set a price target of $76 for CRSP, suggesting a potential increase of 43.21% from its February 13 closing price of $53.07. This optimistic outlook is supported by CRISPR Therapeutics' recent achievements, including the FDA approval of its gene-editing therapy, Casgevy, for sickle cell disease. The approval highlights the company's potential to revolutionize treatment options.
Despite reporting a disappointing fourth quarter with a loss of $1.37 per share and total revenue of only $864,000, CRSP's stock rose by 8.46%. This unexpected increase is largely due to its collaboration with Vertex Pharmaceuticals, which also saw a stock increase of 6.51%. The partnership strengthens CRISPR Therapeutics' position in the biotech industry and enhances its growth prospects. CRISPR Therapeutics' Casgevy therapy generated $54 million in revenue during the fourth quarter of 2025 and $116 million for the entire year. The therapy's adoption is growing, with 147 patients beginning treatment in 2025, nearly tripling from the previous year. This expansion is expected to drive higher revenue in 2026, as noted by William Blair, who highlighted the increase in patient initiations.
The stock for CRSP closed at $53.07 on February 13, reflecting an 8.46% increase from the prior day. It fluctuated between $49.62 and $54.10 on February 13, with a market capitalization of approximately $5.09 billion. The trading volume was 2,465,000 shares on the NASDAQ exchange. Despite challenges, CRISPR Therapeutics' innovative technology and strategic partnerships position it for potential growth.
